A mode-of-action ontology model for safety evaluation of chemicals: Outcome of a series of workshops on repeated dose toxicity.


Journal

Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 07 02 2019
revised: 02 04 2019
accepted: 03 04 2019
pubmed: 8 4 2019
medline: 24 12 2019
entrez: 8 4 2019
Statut: ppublish

Résumé

Repeated dose toxicity evaluation aims at assessing the occurrence of adverse effects following chronic or repeated exposure to chemicals. Non-animal approaches have gained importance in the last decades because of ethical considerations as well as due to scientific reasons calling for more human-based strategies. A critical aspect of this challenge is linked to the capacity to cover a comprehensive set of interdependent mechanisms of action, link them to adverse effects and interpret their probability to be triggered in the light of the exposure at the (sub)cellular level. Inherent to its structured nature, an ontology addressing repeated dose toxicity could be a scientific and transparent way to achieve this goal. Additionally, repeated dose toxicity evaluation through the use of a harmonized ontology should be performed in a reproducible and consistent manner, while mimicking as accurately as possible human physiology and adaptivity. In this paper, the outcome of a series of workshops organized by Cosmetics Europe on this topic is reported. As such, this manuscript shows how experts set critical elements and ways of establishing a mode-of-action ontology model as a support to risk assessors aiming to perform animal-free safety evaluation of chemicals based on repeated dose toxicity data.

Identifiants

pubmed: 30954655
pii: S0887-2333(19)30109-2
doi: 10.1016/j.tiv.2019.04.005
pii:
doi:

Substances chimiques

Cosmetics 0
Hazardous Substances 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-50

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Bertrand Desprez (B)

Cosmetics Europe Science & Research Department, Herrmann-Debrouxlaan 40, 1060 Brussels, Belgium. Electronic address: BDesprez@cosmeticseurope.eu.

Barbara Birk (B)

Experimental Toxicology and Ecology, BASF SE, Carl-Bosch-Strasse 38, 67056 Ludwigshafen, Germany.

Bas Blaauboer (B)

Institute for Risk Assessment Sciences, Division of Toxicology, Utrecht University, PO Box 80.177, 3508TD, Utrecht, the Netherlands.

Alan Boobis (A)

Centre for Pharmacology & Therapeutics, Imperial College London, Hammersmith Campus, Ducane Road, London W12 0NN, United Kingdom.

Paul Carmichael (P)

Safety & Environmental Assurance Centre, Unilever, Colworth Science Park, Sharnbrook, Bedfordshire MK43 7DW, United Kingdom.

Mark T D Cronin (MTD)

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, United Kingdom.

Richard Curie (R)

Product Safety, Syngenta Jealotts Hill International Research Centre, Bracknell, Berkshire RG42 6EY, United Kingdom.

George Daston (G)

Global Product Stewardship, Procter & Gamble, 8700 Mason Montgomery Road, Cincinnati, OH, USA.

Bruno Hubesch (B)

LRI Programme, Cefic, Rue Belliard 40, 1040 Brussels, Belgium; HubeschConsult BVBA, Madeliefjeslaan 10, 1600 Sint-Pieters-Leeuw, Belgium.

Paul Jennings (P)

Division of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, the Netherlands.

Martina Klaric (M)

Cosmetics Europe Science & Research Department, Herrmann-Debrouxlaan 40, 1060 Brussels, Belgium.

Dinant Kroese (D)

Department of Risk Analysis for Products in Development, TNO Healthy Living Unit, Utrechtseweg 48, 3704 HE Zeist, the Netherlands.

Catherine Mahony (C)

Central Product Safety, Procter & Gamble Technical Centres Ltd, Whitehall Lane, Egham, Surrey, TW209NW, United Kingdom.

Gladys Ouédraogo (G)

L'Oreal R&I, Alternative Methods and Reconstructed Skin Department, 1 Avenue Eugene Schueller, 93601 Aulnay sous bois, France; Center for Health Protection, National Institute for Public Health and the Environment, Leeuwenhoeklaan 9, 3720BA Bilthoven, The Netherlands.

Aldert Piersma (A)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.

Andrea-Nicole Richarz (AN)

European Commission, Joint Research Centre, Ispra, Italy.

Michael Schwarz (M)

Department of Experimental and Clinical Pharmacology and Toxicology, Department of Toxicology, Eberhard Karls University, Tübingen, Wilhelmstrasse 56, 72074 Tübingen, Germany.

Jan van Benthem (J)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.

Bob van de Water (B)

Division of Drug Discovery and Safety/Leiden Cell Observatory High Content Imaging Screening Facility, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, the Netherlands.

Mathieu Vinken (M)

Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH